Paper Details

  1. Home
  2. Paper Details

A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).

Author: Bova-SolemMisty, CarlisleDestin, EfeberaYvonne A, HassounHani, LaubachJacob P, McCarthyPhilip L, MulkeyFlora, RichardsonPaul G, SantoKatelyn, SumanVera J, TuchmanSascha A, VoorheesPeter M

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Ixazomib (IXA) is a promising oral proteasome inhibitor that has demonstrated activity in bortezomib-resistant multiple myeloma (MM). A phase I/II clinical trial showed that IXA, combined with pomalidomide (POM) and dexamethasone (DEX), was well tolerated and demonstrated a significant overall response rate in patients with lenalidomide (LEN)/PI-refractory MM.
Paper Details　
Original Abstract of the Article :
Preclinical studies have demonstrated activity of the oral proteasome inhibitor (PI) ixazomib (IXA) in bortezomib-resistant multiple myeloma (MM) and synergy with immunomodulatory drugs. We therefore conducted a phase I/II study to establish the safety and preliminary efficacy of IXA with pomalidomi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/34559902

データ提供：米国国立医学図書館（NLM）

A Novel Treatment Regimen for Lenalidomide and Proteasome Inhibitor Refractory Multiple Myeloma

Multiple myeloma is a complex and challenging hematologic malignancy requiring innovative treatment approaches. This research investigates the safety and efficacy of a novel all-oral regimen combining ixazomib, pomalidomide, and dexamethasone in patients with lenalidomide and proteasome inhibitor refractory multiple myeloma (MM). The study explores the safety profile of this regimen and provides preliminary efficacy data, highlighting its potential as a valuable treatment option for patients with relapsed/refractory MM.

A Promising Treatment Option for Refractory Multiple Myeloma

The study's findings demonstrate that the all-oral regimen of ixazomib, pomalidomide, and dexamethasone is well-tolerated and shows promising efficacy in patients with lenalidomide and proteasome inhibitor refractory MM. The observed response rates and duration of response suggest the potential for this regimen to significantly improve outcomes for patients with relapsed/refractory MM.

Improving Outcomes for Patients with Multiple Myeloma

The development of novel treatment regimens like the ixazomib-pomalidomide-dexamethasone combination is crucial for improving outcomes for patients with multiple myeloma. This research highlights the potential of this regimen to provide effective treatment for patients with relapsed/refractory MM, offering hope for those facing challenging therapeutic situations.

Dr. Camel's Conclusion

Just as a camel adapts to the harsh desert environment, researchers are constantly adapting treatment strategies to combat the challenges of multiple myeloma. This research provides a promising new treatment regimen for refractory MM, offering hope for patients seeking effective therapies.

Date :
  1. Date Completed 2022-01-03
  2. Date Revised 2022-12-13
Further Info :

Pubmed ID

34559902

DOI: Digital Object Identifier

NIHMS1742844

Related Literature

Article Analysis
・Effects of ixazomib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.